Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy

被引:177
作者
Salvatore, S. [1 ,2 ]
Nappi, R. E. [3 ,4 ]
Parma, M. [1 ,2 ]
Chionna, R. [1 ,2 ]
Lagona, F. [1 ,2 ]
Zerbinati, N. [5 ]
Ferrero, S. [6 ,7 ]
Origoni, M. [1 ,2 ]
Candiani, M. [1 ,2 ]
Maggiore, U. Leone Roberti [1 ,2 ]
机构
[1] Univ Vita Salute San Raffaele, Obstet & Gynecol Unit, I-20132 Milan, Italy
[2] IRCCS San Raffaele Hosp, I-20132 Milan, Italy
[3] IRCCS Policlin S Matteo Fdn, Res Ctr Reprod Med Gynecol Endocrinol & Menopause, Pavia, Italy
[4] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, I-27100 Pavia, Italy
[5] Univ Insubria, Varese, Italy
[6] IRCCS San Martino Hosp, Dept Obstet & Gynecol, Genoa, Italy
[7] Univ Genoa, Natl Inst Canc Res, Genoa, Italy
关键词
FRACTIONAL CO2 LASER; MENOPAUSE; VAGINAL DRYNESS; DYSPAREUNIA; SEXUAL FUNCTION; SEXUAL INTERCOURSE; VULVOVAGINAL ATROPHY; FUNCTION INDEX FSFI; POSTMENOPAUSAL WOMEN; HORMONE-THERAPY; ESTROGEN THERAPY; HEALTH; ATTITUDES; IMPACT; MENOPAUSE; SYMPTOMS; EFFICACY;
D O I
10.3109/13697137.2014.975197
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To investigate the effects of fractional microablative CO2 laser on sexual function and overall satisfaction with sexual life in postmenopausal women with vulvovaginal atrophy (VVA). Method This prospective study included 77 postmenopausal women (mean age 60.6 +/- 6.2 years) treated for VVA symptoms with the fractional microablative CO2 laser system (SmartXide(2) (VLR)-L-2, Monalisa Touch, DEKA, Florence, Italy). Sexual function and quality of life were evaluated with the Female Sexual Function Index (FSFI) and the Short Form 12 (SF-12), respectively, both at baseline and at 12-week follow-up. A 10-mm visual analog scale was used to measure the overall satisfaction with sexual life and the intensity of VVA symptoms (vaginal burning, vaginal itching, vaginal dryness, dyspareunia and dysuria) before and after the study period. Results We observed a significant improvement in the total score and the scores in each specific domain of the FSFI at 12-week follow-up compared to baseline (p < 0.001). After concluding the laser treatment, the overall satisfaction with sexual life significantly improved (p < 0.001). Seventeen (85%) out of 20 (26%) women, not sexually active because of VVA severity at baseline, regained a normal sexual life at the 12-week follow-up. Finally, we also found a significant improvement in each VVA symptom (p < 0.001) and in quality-of-life evaluation, both for the scores in the physical (p = 0.013) and mental (p = 0.002) domains. Conclusions Fractional microablative CO2 laser treatment is associated with a significant improvement of sexual function and satisfaction with sexual life in postmenopausal women with VVA symptoms.
引用
收藏
页码:219 / 225
页数:7
相关论文
共 50 条
[1]   Therapeutic options for postmenopausal female sexual dysfunction [J].
Al-Azzawi, F. ;
Bitzer, J. ;
Brandenburg, U. ;
Castelo-Branco, C. ;
Graziottin, A. ;
Kenemans, P. ;
Lachowsky, M. ;
Mimoun, S. ;
Nappi, R. E. ;
Palacios, S. ;
Schwenkhagen, A. ;
Studd, J. ;
Wylie, K. ;
Zahradnik, H. -P. .
CLIMACTERIC, 2010, 13 (02) :103-120
[2]   Efficacy and tolerability of local estrogen therapy for urogenital atrophy [J].
Archer, David F. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2010, 17 (01) :194-203
[3]   Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation [J].
Avis, Nancy E. ;
Brockwell, Sarah ;
Randolph, John F., Jr. ;
Shen, Shunhua ;
Cain, Virginia S. ;
Ory, Marcia ;
Greendale, Gail A. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2009, 16 (03) :442-452
[4]   SEXUALITY IN SEXAGENARIAN WOMEN [J].
BACHMANN, GA ;
LEIBLUM, SR .
MATURITAS, 1991, 13 (01) :43-50
[5]   Listening to Placebo in Clinical Trials for Female Sexual Dysfunction [J].
Bradford, Andrea .
JOURNAL OF SEXUAL MEDICINE, 2013, 10 (02) :451-459
[6]   The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction [J].
Bump, RC ;
Mattiasson, A ;
Bo, K ;
Brubaker, LP ;
DeLancey, JOL ;
Klarskov, P ;
Shull, BL ;
Smith, ARB .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 175 (01) :10-17
[7]   Urogenital atrophy [J].
Calleja-Agius, J. ;
Brincat, M. P. .
CLIMACTERIC, 2009, 12 (04) :279-285
[8]   A comparison of raloxifene and calcium plus Vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women - A randomized, masked-evaluator, one-year, prospective study [J].
Checa, MA ;
Garrido, A ;
Prat, M ;
Conangla, M ;
Rueda, C ;
Carreras, R .
MATURITAS, 2005, 52 (01) :70-77
[9]   Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health [J].
de Villiers, T. J. ;
Pines, A. ;
Panay, N. ;
Gambacciani, M. ;
Archer, D. F. ;
Baber, R. J. ;
Davis, S. R. ;
Gompel, A. A. ;
Henderson, V. W. ;
Langer, R. ;
Lobo, R. A. ;
Plu-Bureau, G. ;
Sturdee, D. W. .
CLIMACTERIC, 2013, 16 (03) :316-337
[10]   A prospective population-based study of menopausal symptoms [J].
Dennerstein, L ;
Dudley, EC ;
Hopper, JL ;
Guthrie, JR ;
Burger, HG .
OBSTETRICS AND GYNECOLOGY, 2000, 96 (03) :351-358